Nuvectis Pharma (NVCT) risk factors
Item 1A of every Nuvectis Pharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks9 new8 dropped16 reworded
Nuvectis Pharma ceased clinical development of NXP800 following its Phase 1b study while maintaining focus on NXP900, bringing new risks regarding supply chain, staffing, and regulatory hurdles.
Filed Feb 11, 2026 - FY2024 10-K risk factors52 risks
Nuvectis Pharma faces substantial clinical development and regulatory risks for its primary oncology product candidates NXP800 and NXP900. The company depends heavily on licensed intellectual property, third-party contractors, and key personnel to execute clinical trials. Operating as a public company with ongoing financial losses increases compliance costs and capital requirements.
Filed Feb 25, 2025